The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.
In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.
A predictive tool, POC Advisor, has been developed to support faster diagnosis and intervention of this dangerous condition.
During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.
The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.
Matt Henn, chief scientific officer at Seres Therapeutics, discusses new ways of targeting infectious diseases and antimicrobial resistant infections.
The proposed funding will include a number of measures of spending towards HIV and prevention, including community centers for PrEP education.
Antimicrobial resistance is “the silent pandemic,” Dr. Leonard Friedland says, and vaccines are how we fight it.
Christian Lillis, co-founder and executive director of the Peggy Lillis Foundation (PLF) for C diff Education & Advocacy, says that taking care of each other is often the best way to stop the spread of infectious diseases.
HIV Stakeholders weigh on the future of PrEP.
As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.
Providers and key stakeholders weigh in on this significant topic.
CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.
Betsy Wonderly-Trainor discusses CARB-X's mission to fund novel antibiotics, preventatives, and diagnostics in the fight against antimicrobial resistance.
How 1 provider is training medical peers to offer PrEP education and prescribe it.
Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.
Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.
India is the world’s leading consumer of antibiotics, and Amita Gupta, MD, is researching how the country can best mitigate the spread of antimicrobial resistance.
Antimicrobial stewardship efforts need infectious disease doctors, but they are in short supply. Telehealth may be the answer.
Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.
During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.
Dr. Nicola Petrosillo discusses treating C difficile infection and maintaining antimicrobial stewardship during the height of the COVID-19 pandemic in Italy.
Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.
Dr. Tamás Haidegger talks about his work to develop an AI-based scanner that tracks hand hygiene to prevent C difficile and other infections.
At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.
Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.
Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.
Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.
The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.
Suzan Walters, PhD, discusses her research on the PrEP care continuum among people who inject drugs in rural versus urban settings.
